IL17A and inflammatory bowel disease: It is recommended that, before initiating IL-17 inhibitor therapy, patients undergo a thorough pre-treatment screening, including evaluation of gastrointestinal symptoms, family history of IBD, and, where appropriate, fecal calprotectin or occult blood testing.